Skip to main content
Oncoimmunology logoLink to Oncoimmunology
. 2022 Nov 18;11(1):2145651. doi: 10.1080/2162402X.2022.2145651

Correction

PMCID: PMC9677990  PMID: 36419824

Article title: Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL

Authors: Blanco G, Vardi A, Puiggros A, Gómez- Llonín A, Muro M, Rodríguez-Rivera M, Stalika E, Abella E, Gimeno E, López-Sánchez M, et al.

Journal: Oncoimmunology

Bibliometrics: Volume 7, Number 6, pages e1432328-1–e1432328-9

DOI: http://dx.doi.org/10.1080/2162402X.2018.1432328

When this article was first published online, there were some data errors in the first paragraph of the Introduction section. These have now been corrected and republished. The revised paragraph is as follows:

Clinical CLL-like monoclonal B cell lymphocytosis (MBL) is characterized by the presence of a clonal population of B lymphocytes in the peripheral blood (0.5 to <5 x 109/L) having a phenotype consistent with chronic lymphocytic leukemia (CLL). It is an asymptomatic condition, yet considered to be a premalignant precursor of CLL, with a progression rate of 1.1% per year to CLL requiring therapy. In fact, the great majority of CLL are preceded by an MBL stage.1–3 Therefore, the study of MBL is critical to understand CLL ontogenesis and clinical evolution.


Articles from Oncoimmunology are provided here courtesy of Taylor & Francis

RESOURCES